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ABSTRACT	
Background:	Cortical	glutamatergic	dysfunction	is	thought	to	be	fundamental	for	psychosis	
development,	 and	 may	 lead	 to	 structural	 degeneration	 through	 excitotoxicity.	 Glutamate	
levels	have	been	related	to	gray	matter	volume	(GMV)	alterations	in	people	at	ultra-high	risk	
of	psychosis,	 and	we	previously	 reported	GMV	changes	 in	 individuals	with	high	 schizotypy	
(HS),	which	refers	 to	the	expression	of	schizophrenia-like	characteristics	 in	healthy	people.	
This	study	sought	to	examine	whether	GMV	changes	in	HS	subjects	are	related	to	glutamate	
levels.		
Methods:	We	 selected	 twenty-two	healthy	 subjects	with	HS	 and	 23	 healthy	 subjects	with	
low	 schizotypy	 (LS)	 based	 on	 their	 rating	 on	 a	 self-report	 questionnaire	 for	 psychotic-like	
experiences.	Glutamate	levels	were	measured	in	the	bilateral	anterior	cingulate	cortex	(ACC)	
using	proton	magnetic	 resonance	 spectroscopy,	 and	GMV	was	 assessed	using	 voxel-based	
morphometry.		
Results:	 Subjects	 with	 HS	 showed	 GMV	 decreases	 in	 the	 rolandic	 operculum/superior	
temporal	gyrus	(pFWE	=	0.045).	Significant	increases	in	GMV	were	also	detected	in	HS,	in	the	
precuneus	 (pFWE	 =	0.043),	 thereby	 replicating	our	previous	 finding	 in	a	 separate	 cohort,	 as	
well	as	in	the	ACC	(pFWE	=	0.041).	While	the	HS	and	LS	groups	did	not	differ	in	ACC	glutamate	
levels,	in	HS	subjects	ACC	glutamate	was	negatively	correlated	with	ACC	GMV	(pFWE	=	0.026).	
Such	association	was	absent	in	LS.		
Conclusions:	 Our	 study	 shows	 that	 GMV	 findings	 in	 schizotypy	 are	 related	 to	 glutamate	
levels,	supporting	the	hypothesis	that	glutamatergic	function	may	lead	to	structural	changes	
associated	with	the	expression	of	psychotic-like	experiences.			
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INTRODUCTION	
Reductions	 in	 gray	 matter	 volume	 have	 been	 extensively	 reported	 in	 patients	 with	
schizophrenia,	 predominantly	 in	 temporal,	 frontal	 and	 parietal	 brain	 regions	 (Bora	 et	 al.,	
2011,	 Chan	 et	 al.,	 2011,	 Haijma	 et	 al.,	 2013).	 Such	 volumetric	 decreases	 are	 also	 found,	
albeit	 attenuated,	 in	 unaffected	 relatives	 of	 schizophrenia	 probands	 (Boos	 et	 al.,	 2007,	
McDonald	et	al.,	2008),	and	 in	subjects	at	ultra-high	risk	 (UHR)	 for	psychosis	 (Fusar-Poli	et	
al.,	2011).	In	UHR	individuals,	gray	matter	volume	reductions	in	medial	temporal	regions	are	
shown	 to	 predict	 subsequent	 transition	 to	 psychosis	 (Mechelli	 et	 al.,	 2011)	 and,	
longitudinally,	an	accelerated	thinning	of	frontal	areas	has	been	associated	with	progression	
to	 psychosis	 (Cannon	 et	 al.,	 2015).	 However,	 the	 neurobiological	 mechanisms	 underlying	
volumetric	 changes	 in	patients	with	psychosis	and	 in	people	with	 subclinical	psychotic-like	
experiences	are	unclear.	 	
	
A	possible	mechanism	for	neuroanatomical	changes	in	psychosis	is	hypofunction	of	
the	N-methyl	D-aspartate	(NMDA)	glutamate	receptor	(Abbott	and	Bustillo,	2006,	Deutsch	et	
al.,	 2001).	 NMDA-receptor	 dysfunction	 is	 found	 to	 lead	 to	 insufficient	 excitation	 of	
GABAergic	 inhibitory	 interneurons,	 downregulating	 their	 activity	 and	 consequently	
increasing	activity	of	pyramidal	glutamatergic	neurons;	 this	may	 in	 turn	 result	 in	excessive	
glutamate	concentrations	around	neurons	and	potentially	in	excitotoxicity	through	the	influx	
of	 calcium	 ions	 (Choi,	 1994).	 Thus,	 excessive	 glutamate	 is	 proposed	 as	 a	mechanism	 that	
would	give	rise	to	alterations	 in	gray	matter	volume	 in	schizophrenia	and	groups	at	risk	of	
developing	the	disorder	(Port	and	Agarwal,	2011).		
	
Increased	 concentrations	 of	 glutamatergic	 metabolites	 are	 observed	 in	
schizophrenia	across	several	cortical	areas	(Marsman	et	al.,	2013,	Merritt	et	al.,	2016),	and	
prefrontal	 elevations	 in	 levels	 of	 Glx	 (glutamate	 +	 glutamine)	 are	 found	 in	 antipsychotic-
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naïve	individuals	at	UHR	for	psychosis	(Merritt	et	al.,	2016),	highlighting	a	role	for	abnormal	
levels	of	glutamatergic	metabolites	in	increasing	psychosis	vulnerability.	Currently,	however,	
human	 imaging	 studies	 provide	 only	 limited	 evidence	 to	 support	 the	 hypothesis	 that	
increased	glutamate	signaling	may	lead	to	excitotoxicity	and	reduced	gray	matter	volume.	In	
support	of	this	hypothesis,	there	are	negative	relationships	between	caudate	Glx	levels	and	
caudate	volume	in	first	episode	psychosis	(Plitman	et	al.,	2016),	left	hippocampal	Glx	levels	
and	 left	hippocampal	volume	 in	unmediated	patients	 (Kraguljac	et	al.,	2013),	and	thalamic	
glutamate	 levels	 and	 cingulate	 cortex	 volume	 in	 UHR	 subjects	 (Stone	 et	 al.,	 2009).	 In	
contrast,	 positive	 relationships	 between	 thalamic	 glutamate	 metabolite	 levels	 and	 more	
widespread	volumetric	 reductions	have	also	been	 reported	 (Aoyama	 et	al.,	2011,	Stone	 et	
al.,	 2009,	 Theberge	 et	 al.,	 2007).	 Given	 that	 brain	 glutamate	 levels	 can	 be	 affected	 by	
antipsychotic	 treatment	 (Egerton	 et	 al.,	 2017),	 further	 evidence	 in	 antipsychotic-naïve	
individuals	 may	 help	 clarify	 the	 relationship	 between	 glutamate	 levels	 and	 gray	 matter	
changes	associated	with	psychosis.	
		
Consistent	 with	 a	 continuum	 model	 of	 psychosis,	 which	 proposes	 dimensional	
continuity	 between	 subclinical	 psychotic-like	 experiences	 in	 healthy	 individuals	 (or	
schizotypy)	 and	 in	 clinically	 relevant	 psychosis	 (Linscott	 and	 van	 Os,	 2013,	 Nelson	 et	 al.,	
2013),	 volumetric	 changes	 have	 also	 been	 documented	 in	 schizotypy	 (Modenato	 and	
Draganski,	2015).	While	the	majority	of	healthy	people	with	schizotypy	as	identified	through	
self-report	 questionnaires	 are	 not	 expected	 to	 develop	 psychosis,	 high	 schizotypy	 is	
associated	 with	 higher	 risk	 for	 developing	 a	 psychotic	 disorder	 (Kwapil	 et	 al.,	 2013),	 and	
represents	 a	 useful	 and	 widely	 applied	 paradigm	 to	 investigate	 neurobiological	 factors	
associated	 with	 schizophrenia	 spectrum	 disorders	 (Barrantes-Vidal	 et	 al.,	 2015).	 High	
schizotypy	involves	typically	non-treatment-seeking	individuals	from	the	general	population	
who	are	commonly	identified	through	psychometrically	validated	self-report	measures,	such	
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as	 the	 Oxford	 and	 Liverpool	 Inventory	 of	 Feelings	 and	 Experiences	 (O-LIFE)	 questionnaire	
(Mason	et	al.,	2005),	or	the	Schizotypal	Personality	Questionnaire	(SPQ)	(Raine,	1991).	After	
our	initial	report	of	increased	gray	matter	volume	in	posterior	cortical	midline	areas	in	high	
schizotypy	 (Modinos	 et	 al.,	 2010),	 subsequent	 studies	 found	 decreases	 in	 other	 fronto-
temporal	regions	including	the	anterior	cingulate	cortex	(Ettinger	et	al.,	2012,	Nenadic	et	al.,	
2015,	 Satterthwaite	 et	 al.,	 2016,	 Wang	 et	 al.,	 2015),	 while	 also	 a	 positive	 association	
between	posterior	cortical	midline	volume	and	schizotypy	scores	was	reported	(Nenadic	et	
al.,	 2015).	 Furthermore,	 a	 more	 recent	 study	 described	 both	 negative	 and	 positive	
associations	 between	 gray	 matter	 volume	 and	 the	 degree	 of	 schizotypy,	 with	 negative	
correlations	 involving	 frontal	 and	 temporal	 lobes	 and	 positive	 correlations	 comprising	
parietal,	 temporal	and	subcortical	 regions	 (Wiebels	et	al.,	2016).	With	regard	to	glutamate	
levels	in	schizotypy,	we	recently	reported	no	differences	between	high	and	low	schizotypes	
in	 the	 anterior	 cingulate	 cortex,	 although	 the	 striking	 finding	 in	 this	 group	 was	 that	
glutamate	levels	were	associated	with	increased	neural	response	to	emotion	in	the	striatum,	
medial	prefrontal	cortex	and	amygdala	(Modinos	et	al.,	2017).	Since	replication	studies	are	
infrequent	 in	 neuroimaging	 research,	 and	 considering	 that	 the	 high	 schizotypy	 paradigm	
allows	 investigation	 of	 neurobiological	 processes	 on	 the	 psychosis	 continuum	 without	
confounding	 effects	 of	 exposure	 to	 previous	 antipsychotic	 treatment	 or	 illness	 chronicity,	
our	 study	 sought	 to	address	 the	 issue	of	whether	 the	predicted	alterations	 in	gray	matter	
volume	 in	 high	 schizotypy	 subjects	 would	 be	 related	 to	 glutamate	 levels	 in	 the	 anterior	
cingulate	cortex.	The	cingulate	cortex	was	chosen	given	that	abnormalities	in	glutamatergic	
metabolites	in	this	region	are	particularly	apparent	in	the	at-risk	stage	of	psychosis	(Merritt	
et	 al.,	 2016),	 and	 that	 altered	 anterior	 cingulate	 volume	 has	 been	 found	 in	 schizotypy	
(Ettinger	et	al.,	2012).	We	tested	the	hypothesis	that	volumetric	changes	in	high	schizotypy	
individuals	 would	 be	 negatively	 correlated	with	 glutamate	 levels	 in	 the	 anterior	 cingulate	
cortex.	
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MATERIALS	AND	METHODS	
Participants	
The	recruitment	procedure	is	described	in	detail	in	our	recent	article	(Modinos	et	al.,	2017).	
Briefly,	two-hundred	and	fifty	healthy	volunteers	who	responded	to	the	Research	Volunteer	
Recruitment	Webpage	of	King’s	College	London	were	pre-screened	with	the	short	version	of	
the	O-LIFE	questionnaire	(Mason	et	al.,	2005).	Participants	with	high	scores	on	the	Unusual	
Experiences	(UE)	subscale	of	the	O-LIFE	(UE	score	>7,	HS	group),	and	participants	with	 low	
levels	of	UE	(score	<2,	LS	group)	were	then	invited	to	participate,	following	previous	imaging	
research	 in	 HS	 (Premkumar	 et	 al.,	 2012).	 The	UE	 subscale	 of	 the	O-LIFE	was	 used	 as	 it	 is	
associated	 with	 higher	 severity	 of	 positive	 symptoms	 in	 schizophrenia	 (Cochrane	 et	 al.,	
2010),	and	our	first	neuroanatomical	study	in	schizotypy	had	also	selected	individuals	based	
on	positive-dimension	scores	on	a	similar	self-report	instrument	(Modinos	et	al.,	2010).		
	
Twenty-three	individuals	were	included	in	the	HS	group	(11	females;	age	range,	18–
55	years;	mean	age	28.48	years)	and	23	in	the	LS	group	(11	females;	age	range,	18–58	years;	
mean	 age	 28.36	 years).	 Participants	 with	 personal	 history	 of	 neurologic	 or	 psychiatric	
disorders	were	excluded,	as	assessed	with	the	Mini	International	Neuropsychiatric	Inventory	
(Sheehan	et	al.,	1998),	administered	by	a	trained	interviewer.	All	participants	were	MRI-safe,	
and	none	had	used	recreational	drugs	in	the	two	weeks	prior	to	magnetic	resonance	imaging	
(MRI)	 scanning,	 or	 met	 criteria	 for	 substance	 abuse/dependency	 by	 self-report.	 Of	 note,	
there	was	no	sample	overlap	between	the	current	study	and	our	previous	volumetric	study	
in	 HS	 (Modinos	 et	 al.,	 2010).	 All	 participants	 gave	written	 informed	 consent	 to	 the	 study	
protocol,	which	was	approved	by	the	King’s	College	London	Research	Ethics	Committee.	The	
authors	 assert	 that	 all	 procedures	 contributing	 to	 this	 work	 comply	 with	 the	 ethical	
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standards	of	the	relevant	national	and	institutional	committees	on	human	experimentation	
and	with	the	Helsinki	Declaration	of	1975,	as	revised	in	2008.	
	
Assessments	
Subjects	 completed	 the	 following	 assessments	 before	 scanning	 commenced:	 a	 validated	
short	version	of	the	Wechsler	Adult	Intelligence	Scale-III	(WAIS-III)	(Velthorst	et	al.,	2013);	a	
semi-structured	 interview	 adapted	 from	 the	 Early	 Psychosis	 Prevention	 and	 Intervention	
Centre	 (EPPIC)	Drug	and	Alcohol	Assessment	Schedule	 (http://www.eppic.org.au)	to	assess	
current/past	medication	use,	current/past	use	of	alcohol,	tobacco,	and	illicit	drugs;	and	the	
Social	Functioning	Questionnaire	(SFQ)	(Tyrer	et	al.,	2005).		
	
Volumetric	MRI	Protocol		
For	all	subjects,	a	three-dimensional	T1-weighted	inversion	recovery	prepared	gradient	echo	
sequence	was	obtained	on	a	General	Electric	Discovery	MR750	3T	system	(Milwaukee,	WI,	
USA)	at	the	Institute	of	Psychiatry,	Psychology	&	Neuroscience,	King’s	College	London	(voxel	
size:	1.05	x	1.05	x	1.2mm,	field	of	view:	270mm,	196	slices,	TR:	7.3	ms,	TE:	3.0	ms,	inversion	
time:	400	ms,	flip	angle	=	11°,	based	on	the	well	validated	ADNI	2/ADNI	GO	protocols	(see	
http://adni.loni.usc.edu/methods/documents/mri-protocols/).		
	
	 Structural	images	were	preprocessed	using	the	Voxel-Based	Morphometry	protocol	
(Ashburner,	 2010)	 implemented	 in	 SPM12	
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12),	 running	 on	 Matlab	 9.2	 (The	
MathWorks,	 USA).	 The	 following	 steps	 were	 applied:	 (1)	 Segmentation	 of	 all	 images	 into	
gray	matter	(GM),	white	matter	(WM),	and	cerebrospinal	fluid	(CSF)	partitions;	(2)	Warping	
of	GM	partitions	into	a	new	study-specific	reference	space,	to	provide	increased	accuracy	of	
inter-subject	alignment;	(3)	Normalization	of	the	warped	GM	partitions	to	the	MNI	space,	to	
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generate	 smoothed	 (10mm	 FWHM),	 spatially	 normalized	 and	 modulated	 GM	 images	 in	
Montreal	Neuroanatomical	 Imaging	 (MNI)	 space.	Global	GM	volume	 and	 total	 intracranial	
volume	were	calculated.	Global	GM	volume	was	estimated	using	 the	 total	amount	of	gray	
matter	in	the	GM	images	obtained	from	segmentation,	including	the	cerebellar	gray	matter.	
Total	 intracranial	 volume	was	 calculated	 for	 each	 subject	 by	 summing	 together	 the	 voxel	
values	of	GM,	WM	and	CSF	 from	the	original	 tissue	partitions	using	 the	 ImCalc	 function	 in	
SPM12.	
	
1H-MRS	Protocol	and	Quantification	
A	proton	magnetic	resonance	spectrum	(1H-MRS;	PRESS,	Point	RESolved	Spectroscopy)	was	
acquired	during	the	same	scanning	session,	after	the	structural	MRI	scan,	from	the	bilateral	
anterior	cingulate	cortex	(Figure	1A),	as	described	in	previous	studies	from	our	group	in	UHR	
subjects	and	patients	with	first-episode	psychosis	(Egerton	et	al.,	2012,	Egerton	et	al.,	2014,	
Stone	et	al.,	2009),	and	schizotypy	(Modinos	et	al.,	2017).	
	
A	 standard	 GE	 PROBE	 (proton	 brain	 examination)	 sequence	 was	 used,	 which	
incorporates	 a	 standardized	 chemically	 selective	 suppression	 (CHESS)	 water	 suppression	
routine	(TE:	30	ms;	TR:	3000	ms;	96	averages	collected).	For	each	acquisition,	unsuppressed	
water	 reference	 spectra	 (16	 averages)	were	 also	 acquired.	 Shimming	was	 optimized,	with	
auto-prescan	performed	twice	before	each	scan.	The	region	of	interest	(ROI)	in	the	bilateral	
anterior	 cingulate	cortex	 (ACC)	was	prescribed	medially	 from	the	midline	 sagittal	 localizer,	
and	 the	 center	 of	 the	 20	 ×	 20	 ×	 20	mm	ROI	mostly	 covering	 the	 ACC	was	 placed	 16	mm	
above	 the	 anterior	 section	 of	 the	 genu	 of	 the	 corpus	 callosum	 at	 90°	 to	 the	 anterior	
commissure	–	posterior	commissure	(AC-PC)	line.		
	
Psychological	Medicine	 	 Modinos	et	al.	
	 9	
																			Spectra	 were	 analyzed	 using	 LCModel	 version	 6.3-1L	 (http://s-
provencher.com/pages/lcmodel.shtml)	 (Provencher,	 1993).	 Water-scaled	 glutamate	 (Glu),	
Glutamine	(Gln),	Glx	(glutamate	+	glutamine),	myo-Inositol	(mI),	choline	(Cho),	creatine	(Cre)	
and	 N-acetylaspartate	 (NAA)	 values	 were	 corrected	 for	 voxel	 CSF	 using	 the	 formula:	
Metabolite	Corrected	=	Metabolite	Concentration	*	[proportion	WM	+	 (1.283	*	proportion	
GM)	+	 (1.548	 *	 proportion	CSF)]	 /	 (proportion	WM	+	proportion	GM)	 (Provencher,	 2016).	
Voxel	GM,	WM	and	CSF	content	for	each	subject	were	ascertained	by	extracting	the	location	
of	 the	voxel	 from	the	spectra	 file	headers,	and	using	an	 in-house	program	to	calculate	the	
percentage	GM,	WM	and	CSF	using	the	segmented	T1-weighted	 images.	We	used	Cramer-
Rao	minimum	variance	bounds	(CRLB)	>	20%	as	reported	by	LCModel,	which	are	estimates	
of	 fit	 of	 the	metabolite	 peaks,	 and	 signal-to-noise	 ratio	 (SNR)	 <8	 to	 exclude	 poorly-fitted	
metabolite	peaks	from	statistical	analysis	(Mouchlianitis	et	al.,	2016,	Provencher,	2016);	only	
one	 HS	 subject	 exceeded	 the	 CRLB	 threshold	 and	 the	 final	 sample	 thus	 involved	 22	 HS	
subjects	and	23	LS	subjects.	This	sample	largely	overlaps	with	our	recent	publication	in	21	HS	
and	22	LS	subjects	on	functional	MRI–MRS	interactions	(Modinos	et	al.,	2017).	The	primary	
1H-MRS	measure	was	 glutamate	 corrected	 for	 voxel	 CSF.	No	 correction	was	made	 for	 T1-	
and	T2-relaxation	and	metabolite	concentrations	are	given	in	“institutional	units”.		
	
Statistics	
Analysis	 of	 behavioral	 and	 demographic	 data	 was	 performed	 in	 SPSS	 23	 (http://www-
01.ibm.com/software/uk/analytics/spss/).	The	effect	of	group	on	these	measures	was	tested	
using	 independent	 samples	 t-tests	 for	 parametric	 data	 and	 Chi-square	 tests	 for	 non-
parametric	data.	Significant	effects	are	reported	at	p	<	0.05.		
	
1H-MRS	data	analysis		
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Group	 differences	 in	 bilateral	 ACC	 glutamate	 concentrations	 were	 examined	 with	 an	
independent	samples	t-test	in	SPSS.	Exploratory	analyses	of	the	other	metabolites	present	in	
the	spectra	were	also	conducted	with	a	t-test	corrected	for	multiple	comparisons	(threshold	
for	 6	 metabolites,	 1	 voxel;	 p	 =	 0.008).	 Levene’s	 test	 was	 used	 to	 check	 for	 equality	 of	
variance	across	groups.	
	
MRI	data	analysis	
Statistical	analyses	of	MRI	data	were	implemented	in	SPM12	using	an	independent	samples	
t-test,	with	proportional	scaling	of	the	total	intracranial	volume	to	adjust	for	global	effects.	
We	examined	 significant	 group	effects	 in	GM	volume	 in	HS	 and	 LS	using	 a	 voxel-wise	ROI	
approach.	ROIs	in	the	precuneus	and	posterior	cingulate	gyrus	were	specified	a-priori	using	
the	coordinates	from	our	previous	structural	study	in	an	independent	HS	sample	(Modinos	
et	 al.,	 2010)	 and	 in	 the	 ACC	 from	 a	 previous	 UHR	 study	 (Borgwardt	 et	 al.,	 2007a):	 MNI	
coordinates	precuneus	x,	y,	z	=	0,	-54,	44;	posterior	cingulate	gyrus	x,	y,	z	=	2,	-42,	18;	and	
ACC	x,	y,	z	=	-6,	0,	43.	These	coordinates	were	used	for	small	volume	correction	(SVC)	with	a	
10-mm	 sphere.	 For	 all	 tests,	 we	 used	 an	 initial	 voxel-wise	 search	 threshold	 of	 p	 <	 0.005	
uncorrected,	to	then	only	consider	significant	effects	which	survived	voxel-wise	family-wise	
error	(FWE)	correction	for	multiple	comparisons	at	p	<	0.05.	Exploratory	whole	brain	results	
were	analyzed	at	the	same	initial	uncorrected	threshold	for	completeness,	but	only	effects	
surviving	voxel-wise	p	<	0.05	FWE	correction	are	discussed.	
	
Integration	of	MRI	and	1H-MRS	data	
The	 relationship	between	GM	volume	and	glutamate	 levels	 in	 the	ACC	was	established	by	
using	 the	 individual	 glutamate	 concentrations	 as	 a	 regressor	 in	 a	 voxel-wise	 ROI	 ANOVA	
(precuneus,	 posterior	 and	ACC	 as	 described	 above),	 also	 using	 proportional	 scaling	 of	 the	
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total	 intracranial	 volume	 to	 adjust	 for	 global	 effects.	 The	 same	 correction	 for	 multiple	
comparisons	as	described	above	was	used.	
	
Correlations	between	imaging	and	schizotypy	/	social	functioning	levels	
Relationships	 between	 glutamate	 levels	 and	 both	 schizotypy	 scores	 and	 social	 functioning	
levels	 were	 explored	 in	 the	 HS	 group	 using	 Pearson’s	 product	 moment	 correlation,	
correcting	 for	 the	 number	 of	 correlations	 performed	 (threshold	 p	 <	 .05/2	 comparisons	 =	
.025).	To	assess	correlations	between	GM	volume	and	schizotypy	scores	/	social	functioning	
levels	 in	 HS	 individuals,	 two	 separate	 ROI	 regression	 analyses	 using	 the	 individual	 O-LIFE	
total	/	SFQ	total	scores	as	regressor	in	SPM12	were	conducted,	with	the	ROI	coordinates	as	
described	above	and	applying	the	same	correction	for	multiple	comparisons.	
	
	 	
RESULTS	
Demographic	and	questionnaire	data	
Full	demographic	and	behavioral	results	are	presented	in	Table	1.	The	HS	and	LS	groups	only	
differed	significantly	by	design	in	the	schizotypy	measures,	with	HS	subjects	showing	higher	
scores	 than	 those	with	 LS	on	 the	O-LIFE:	 Total	 (p	 <	 .001),	Unusual	 Experiences	 (p	 <	 .001),	
Cognitive	 Disorganization	 (p	 =	 .001),	 and	 Introvertive	 Anhedonia	 (p	 <	 .001).	 High	 positive	
schizotypy	 (UE	 subscale)	 was	 positively	 associated	 with	 the	 CD	 (r	 =	 .505,	 p	 =	 .017)	 and	
marginally	with	the	IA	subscales	(r		=	.381,	p	=	.080).	
	
[Table	1	about	here]	
	
1H-MRS	spectral	quality	
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Spectra	obtained	were	of	good	quality,	with	LCModel	reporting	mean	±	SD	SNR	of	25.6	±	4.6,	
line	width	of	4.9	±	.8	Hz	and	FWHM	of	.04	±	.004.	For	Gln,	only	data	from	9	LS	subjects	and	
11	HS	 subjects	were	usable,	with	a	 similar	number	of	 subjects	 excluded	 from	each	group.	
There	were	 no	 significant	 group	 differences	 in	 any	 of	 the	 parameters	 relating	 to	 spectral	
quality	or	voxel	tissue	content	(Table	2).		
	
Group	differences	in	1H-MRS	
There	was	no	evidence	of	between-group	differences	 in	glutamate	 levels,	or	 in	any	of	 the	
other	metabolites	present	 in	 the	bilateral	ACC	voxel	 (glutamine,	Glx,	myo-inositol,	 choline,	
creatine,	and	N-acetylaspartate;	Figure	1B;	Table	2).	There	were	no	significant	correlations	
between	glutamate	concentrations	and	age	(r	=	-.194,	p	=	.203)	or	caffeine	use	(r	=	.189,	p	=	
.215).	Similarly,	in	the	HS	group	no	associations	were	found	between	GABA	levels	and	social	
functioning	scores	(r	=	.318,	p	=	.149),	or	O-LIFE	total	scores	(r	=	.107,	p	=	.634).	
	
[Figure	1	about	here]	
[Table	2	about	here]	
	
Group	differences	in	gray	matter	volume	
Groups	did	not	differ	in	global	GM	volume	(LS,	mean:	797.54	±	63.15	mm3;	HS,	mean:	784.27	
±	75.29	mm3;	t	=	0.642;	p	=	0.525)	or	total	intracranial	volume	(LS,	mean:	1.0e+03*1.49	±	.14	
mm3;	HS,	mean:	1.0e+03*1.50	±	.11	mm3;	t	=	-0.174;	p	=	0.862).		
	
Exploratory	 whole-brain	 analyses	 revealed	 smaller	 GM	 volume	 in	 HS	 compared	 to	 LS	
subjects	in	a	right-sided	region	including	the	rolandic	operculum	and	the	superior	temporal	
gyrus	 (peak	coordinate	at	x,	 y,	 z	=	58	 -20	14;	T	=	5.07;	Z	=	4.46;	pFWE	=	0.045)	 (Figure	2A).	
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There	were	no	other	significant	whole-brain	effects,	nor	significant	effects	were	identified	in	
our	ROIs	for	the	HS	<	LS	contrast	(voxel-wise	FWE-corrected).	
	
Using	 ROI	 analysis,	 subjects	 with	 HS	 showed	 larger	 GM	 volumes	 in	 the	 precuneus	 (peak	
coordinate	 at	 x,	 y,	 z	 =	 -8	 -50	 46;	 T	 =	 3.03;	 Z	 =	 2.87;	 pFWE	 =	 0.043)	 and	 in	 the	 ACC	 (peak	
coordinate	at	x,	y,	z	=	-9	-8	39;	T	=	3.05;	Z	=	2.89;	pFWE	=	0.041)	(Figure	2B).	Groups	did	not	
differ	 in	age	or	 illicit	drug/alcohol	use,	and	 the	 results	of	 the	GM	volume	comparisons	did	
not	 change	 when	 age	 or	 illicit	 drug/alcohol	 use	 were	 added	 to	 the	 model.	 No	 regions	
survived	voxel-wise	FWE	correction	for	the	HS	>	LS	contrast	at	the	whole	brain	level.		
	
ROI	 regression	 analyses	 were	 used	 to	 assess	 correlations	 between	 GM	 volume	 and	
schizotypal	scores	and	social	functioning.	These	revealed	a	positive	association	between	O-
LIFE	total	scores	and	GM	volume	in	the	precuneus	(peak	coordinate	at	x	y	z	=	0,	-38,	24;	T	=	
3.03;	 Z	 =	 2.72;	 pFWE	 =	 .044),	 as	well	 as	 positive	 association	 between	 SFQ	 total	 scores	 and	
precuneus	volume	(peak	coordinate	at	x	y	z	=	2,	-45,	12;	T	=	3.11;	Z	=	2.77;	pFWE	=	.039).	Thus,	
larger	 GM	 volumes	 in	 the	 precuneus	were	 related	 to	 higher	 schizotypal	 traits	 and	 poorer	
social	functioning	in	HS	individuals.	
	
[Figure	2	about	here]	
	
Relationship	Between	1H-MRS	Measures	and	GMV	
Figure	3	shows	the	relationship	between	glutamate	 levels	and	GM	volume.	 In	HS	subjects,	
ROI	 analysis	 showed	 that	 ACC	 glutamate	 levels	 were	 negatively	 associated	with	 local	 GM	
volume	in	the	ACC.	In	the	ACC,	the	higher	the	ACC	glutamate,	the	smaller	the	volume	of	GM	
(peak	coordinate	at	x,	y,	z	=	-9,	9,	40;	T	=	3.28;	Z	=	3.07;	pFWE	=	0.026)	(Figure	3).	In	terms	of	
positive	associations,	no	regions	survived	correction	 for	multiple	comparisons	 in	HS.	There	
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were	no	significant	correlations	in	LS	subjects	in	either	directionality.	Groups	did	not	differ	in	
age	or	illicit	drug/alcohol	use,	and	the	results	of	the	ACC	glutamate-GM	volume	association	
did	 not	 change	when	 age	 or	 illicit	 drug/alcohol	 use	were	 added	 to	 the	model.	 No	 effects	
survived	voxel-wise	FWE	correction	at	the	whole	brain	level.	
	
A	 secondary	 analysis	 examining	 associations	with	 levels	 of	 Glx	 showed	 a	 trend	 towards	 a	
negative	association	with	GM	volume	in	the	ACC	in	HS	individuals	(peak	coordinate	at	x,	y,	z	
=	-10,	8,	39;	T	=	2.96;	Z	=	2.79	pFWE	=	.051).	
	
[Figure	3	about	here]	
	
	
DISCUSSION	
The	main	aim	of	this	study	was	to	investigate	whether	glutamate	levels	are	associated	with	
gray	 matter	 volume	 in	 healthy	 individuals	 with	 high	 schizotypy,	 similar	 to	 the	 patterns	
observed	 in	 people	 at	 ultra-high	 risk	 of	 psychosis.	 Although	 glutamate	 concentrations	 did	
not	significantly	differ	between	individuals	with	high	and	low	schizotypy,	as	we	have	recently	
reported	 in	an	overlapping	dataset	 (Modinos	 et	al.,	 2017),	 glutamate	 levels	 in	HS	 subjects	
were	negatively	associated	with	GM	volume	in	the	anterior	cingulate	cortex.	This	association	
was	absent	in	the	LS	group.	The	findings	are	not	attributable	to	effects	of	antipsychotics	as	
all	subjects	were	medication-naïve,	and	groups	were	matched	for	demographics,	cognition,	
and	substance	use;	the	only	significant	differences	between	groups	referred	to	the	presence	
of	 subclinical	 psychotic-like	 experiences.	 This	 is	 consistent	 with	 evidence	 that	 levels	 of	
glutamate	 are	 negatively	 correlated	with	 local	 GM	 volume	 in	 antipsychotic-naïve	 patients	
with	first-episode	psychosis	(Kraguljac	et	al.,	2013,	Plitman	et	al.,	2016).	Our	study	extends	
those	 previous	 findings	 in	 caudate	 and	 hippocampus	 by	 showing	 the	 same	 relationship	 in	
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the	 ACC.	 Nevertheless,	 glutamate	 levels	 may	 also	 impact	 on	 more	 widespread	 structural	
changes,	 as	 reported	 in	 subjects	 at	 ultra-high	 risk	 of	 psychosis	 (Stone	 et	 al.,	 2009)	 and	
patients	 with	 first-episode	 psychosis	 (Theberge	 et	 al.,	 2007).	 Regardless	 of	 potentially	
disease-stage	 specific	 findings,	 our	 study	 suggests	 that	 ACC	 glutamate	 concentrations	 are	
related	to	volumetric	changes	 in	schizotypal	 individuals.	Noteworthy,	we	recently	reported	
that	 ACC	 glutamate	 concentrations	 were	 negatively	 correlated	 with	 neural	 response	 to	
emotion	in	brain	regions	robustly	involved	in	the	pathophysiology	of	psychosis	(striatum	and	
marginally	MPFC	 and	 amygdala)	 in	 schizotypy	 (Modinos	 et	 al.,	 2017).	 Our	 results	 suggest	
that	ACC	glutamate	levels	are	related	to	increased	local	GM	volume	as	well	as	to	increased	
corticolimbic	response	to	emotion	 in	HS.	Such	relationships	 in	HS	provide	some	support	to	
preclinical	 models	 postulating	 that	 altered	 prefronto-temporal-striatal	 interactions	 in	
relation	 to	 psychotic-like	 behaviors	 are	 associated	 with	 changes	 in	 cortical	 glutamatergic	
function	(Berretta	et	al.,	2001,	Lodge	and	Grace,	2011).	As	the	normal	function	of	this	circuit	
depends	 on	 a	 proper	 excitation-inhibition	 balance,	 and	 given	 that	 the	 properties	 of	 this	
circuit	appear	to	change	during	adolescence	in	preclinical	models	 (Gomes	et	al.,	2016),	our	
data	provide	some	additional	support	for	a	“staged”	approach	to	the	understanding	of	the	
pathophysiology	 of	 schizophrenia-like	 symptoms	 and	 behaviors	 (Deutsch	 et	 al.,	 2001).	
Collectively,	 these	 findings	 are	 in	 line	with	a	psychosis	 continuum	view	by	 suggesting	 that	
interactions	between	brain	structure	and	neurochemistry	are	 involved	 in	the	expression	of	
psychotic-like	experiences	at	non-clinical	and	clinical	degrees.	These	findings	may	also	serve	
as	 evidence	 of	 potentially	 protective	mechanisms,	 as	 this	 study	 involved	 high-functioning	
individuals	with	HS	and	considering	that,	while	the	association	between	ACC	glutamate	and	
GM	 volume	was	 negative	 in	HS,	 the	 group	 effect	 showed	 increased	 volume	 in	 this	 region	
compared	to	LS	subjects.	These	results	are	opposite	to	the	prediction	from	studies	in	clinical	
groups	 that	 HS	 would	 be	 associated	 with	 higher	 glutamate	 and	 reduced	 volume	 in	 that	
region.	Further	research	examining	the	relative	contributions	of	excitation	and	inhibition	to	
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GM	 volume	 in	 different	 groups	 (schizophrenia,	 UHR,	 HS)	 and	 combining	measurement	 of	
GABA	and	 glutamate	 levels,	may	provide	 substantial	 insights	 into	 the	neurobiology	of	 risk	
and	resilience	for	psychiatric	disorders	(Pantelis	and	Bartholomeusz,	2014).		
	
The	present	study	replicated	our	previous	finding	of	 larger	regional	GM	volumes	in	
the	posterior	cortical	midline	(Modinos	et	al.,	2010)	 in	a	separate	cohort	of	HS	 individuals.	
We	 again	 report	 that	 people	 with	 HS	 had	 increased	 volume	 of	 the	 precuneus	 relative	 to	
comparison	 subjects	with	 low	 levels	 of	 schizotypy,	 an	 area	 involved	 in	 self-awareness	 and	
self-evaluation	and	which	 is	a	core	component	of	the	default-mode	network	(Cavanna	and	
Trimble,	 2006,	 Utevsky	 et	 al.,	 2014).	 Furthermore,	 larger	 precuneus	 volumes	 were	
significantly	related	to	both	higher	levels	of	schizotypy	as	well	as	to	lower	social	functioning	
in	 the	HS	sample,	providing	a	 link	between	 these	neuroanatomical	 findings	and	psychosis-
related	 behaviors.	 A	 similar	 finding	 was	 reported	 by	 another	 study	 showing	 a	 positive	
association	 between	 precuneus	 volume	 and	 schizotypy	 scores	 (Nenadic	 et	 al.,	 2015).	 In	
contrast,	GM	decreases	as	opposed	to	increases	in	this	region	were	found	by	other	groups	in	
people	 at	UHR	of	 psychosis	 (Borgwardt	 et	 al.,	 2007b)	 and	 patients	with	 a	 first	 episode	 of	
psychosis	(Theberge	et	al.,	2007).	Although	these	findings,	taken	together,	may	suggest	that	
volumetric	 changes	 in	 the	 precuneus	 are	 present	 along	 the	 psychosis	 continuum,	 the	
discrepancies	in	directionality	indicate	that	structural	characteristics	of	this	region	may	vary	
based	on	the	degree	of	psychosis	risk	(larger	volumes	in	healthy	people	with	schizotypy,	at	
low	 risk)	 and	 expression	 (smaller	 volumes	 in	 people	 at	 higher	 risk	 or	 clinically	 ill).	 The	
functional	 significance	 of	 larger	 precuneus	 volumes	 associated	 with	 schizotypal	 traits,	 in	
particular,	 remains	 to	 be	 determined.	 One	 possibility	 is	 that	 such	 larger	 volumes,	 while	
associated	with	 some	 of	 the	 subclinical	 features	 of	 psychosis,	may	 offer	 resilience	 to	 the	
development	 of	 a	 clinical	 diagnosis.	 While	 the	 mechanisms	 are	 unclear,	 one	 speculative	
interpretation	is	that	this	may	relate	to	variables	such	as	creativity	and	spirituality,	on	which	
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people	 with	 schizotypal	 traits	 score	 higher	 on	 average.	 Indeed,	 creativity	 has	 been	
associated	with	 larger	precuneus	 volume	and	 thickness	 (Chen	 et	al.,	 2015)	 and	 spirituality	
had	also	been	associated	with	larger	precuneus	volume	(Miller	et	al.,	2014).	Higher	levels	of	
spirituality	and	greater	precuneus	volumes	may	confer	 resilience	to	developing	depression	
(Miller	 et	 al.,	 2014),	 and	 it	 is	 possible	 that	 larger	 volumes	 may	 also	 confer	 resilience	 to	
developing	 psychosis.	 A	 further	 explanation	 may	 be	 that	 these	 neuroanatomical	 changes	
reflect	 plastic	 adaptation	 to	 a	 genetic-	 or	 environment-related	 liability	 for	 psychiatric	
outcomes,	and	enable	psychiatrically	resilient	high	schizotypes	to	effectively	compensate,	in	
line	with	 recent	 postulations	 about	 the	 effects	 of	 early	 life-stress	 on	 brain	 (Teicher	 et	 al.,	
2016).	The	possibility	 that	such	 larger	volumes	may	offer	 resilience	 to	 the	development	of	
clinical	psychosis,	and	the	relationship	with	stress,	deserves	further	investigation.		
	
Further	 group	 effects	 in	 our	 study	 involved	 GM	 volume	 increases	 in	 anterior	
cingulate	gyrus	and	decreases	in	superior	temporal	cortex.	Volumetric	decreases	in	superior	
temporal	 cortex	 areas	 have	 been	 extensively	 associated	with	 schizophrenia	 (Honea	 et	 al.,	
2005,	Radua	et	al.,	2012),	individuals	at	UHR	of	psychosis	(Borgwardt	et	al.,	2008,	Fusar-Poli	
et	 al.,	 2011),	 and	 HS	 (Ettinger	 et	 al.,	 2012).	 In	 the	 anterior	 cingulate	 gyrus,	 however,	 our	
study	 highlights	 an	 additional	 discrepancy	 as	 previous	 studies	 had	 mainly	 reported	
volumetric	decreases.	 Increases	 in	GM	volume	have	been	 suggested	 to	occur	 in	 the	 initial	
stages	 of	 apoptosis	 (Adler	 et	 al.,	 2005),	 a	 process	 in	 which	 glutamatergic	 dysfunction	 is	
thought	 to	 be	 involved,	 so	 one	 possibility	 is	 that	 volumetric	 changes	 across	 the	 psychosis	
spectrum	 are	 dynamic,	 and	 that	 volumetric	 reductions	 occur	 at	 a	 later	 stage	 when	 a	
glutamatergic	alteration	is	identifiable.	However,	no	studies	have	examined	the	relationship	
between	 such	 structural	 findings	 and	 metabolite	 measures	 in	 relation	 to	 subclinical	
psychotic-like	experiences,	and	our	study	suggests	a	direct	link	between	them	in	the	anterior	
cingulate	cortex.		
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There	 are	 some	 limitations	 to	 the	 present	 study.	 Firstly,	 subjects	 were	 recruited	
from	a	university	sample,	had	relatively	high	IQs	and	groups	showed	no	differences	in	self-
reported	 substance	 use;	 therefore,	 our	 results	 may	 not	 generalize	 to	 all	 individuals	 with	
schizotypy.	 Larger	 studies	 in	 general	 population	 samples	 would	 help	 define	 the	 normal	
variation	in	schizotypy.	Secondly,	several	theories	exist	about	the	schizotypy	construct	and	a	
range	of	assessment	 instruments	have	been	developed;	the	present	 investigation	used	the	
O-LIFE	questionnaire,	which	follows	a	personality-based	model	of	schizotypy,	and	therefore	
should	 be	 interpreted	 to	 report	 on	 neurobiological	 correlates	 of	 schizotypal	 traits	 as	
understood	 from	 a	 dimensional	 rather	 than	 a	 clinical	 perspective.	 Thirdly,	 schizotypy	 is	
regarded	as	a	multidimensional	construct	 (Mason	and	Claridge,	2006,	Nelson	et	al.,	2013).	
While	 the	 HS	 group	 was	 formed	 based	 on	 high	 UE	 scores,	 thus	 reflecting	 high	 positive	
schizotypy,	groups	also	differed	 in	the	CD	and	 IA	subscales;	this	might	have	contributed	to	
the	present	results	and	future	studies	should	seek	to	explicitly	explore	the	other	schizotypy	
dimensions.	 Furthermore,	 this	 cross-sectional	 study	 does	 not	 allow	 evaluation	 of	whether	
the	observed	GM	changes	are	driven	by	HS	subjects	who	may	later	develop	a	mental	health	
disorder	(Cannon	et	al.,	2015).	With	regards	to	MRS	methodology,	1H-MRS	measurements	of	
glutamate	 and	 glutamine	 reflect	 the	 combined	 intra-	 and	 extra-neuronal	 metabolite	
concentration,	and	using	our	approach	of	PRESS	with	a	TE	of	30	ms	at	3	Tesla	the	partially	
overlapping	 signals	 from	 glutamate	 and	 glutamine	 cannot	 be	 entirely	 resolved,	 with	
contamination	of	 the	Glu	 signal	by	Gln	estimated	as	<10%	 (Snyder	and	Wilman,	2010).	Of	
note,	 groups	 did	 not	 differ	 significantly	 in	 either	 glutamine	 or	Glx.	 This	 aligns	with	 recent	
results	showing	that	chronicity	of	psychotic	symptoms	is	associated	with	decreased	levels	of	
Glx	 in	 a	 study	 comparing	 chronic	 schizophrenia	 patients,	 patients	 with	 recent	 onset	
psychotic	disorder,	and	ultra-high	risk	 individuals	 (Liemburg	et	al.,	2016)	and	suggests	that	
detectable	1H-MRS	differences	in	non-clinical	groups	may	be	very	subtle.	We	cannot	rule	out	
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the	possibility	that	the	lack	of	significant	differences	in	the	standalone	1H-MRS	measures	are	
related	 to	 limited	 power	 in	 this	 non-clinical	 sample	 and	 this	will	 need	 to	 be	 replicated	 by	
independent	studies	of	larger	samples.	 Finally,	we	employed	a	self-report	of	use	of	drugs	of	
abuse	but	future	studies	should	consider	adding	a	drug	screening	test	prior	to	scanning.	
	 	
The	 present	 study	 suggests	 that	 gray	 matter	 volume	 changes	 in	 cortical	 midline	
areas	 are	 associated	 with	 glutamate	 levels	 in	 subjects	 with	 high	 schizotypy,	 with	 such	
findings	 not	 being	 dependent	 on	 disease	 chronicity	 or	 the	 confounding	 influence	 of	
antipsychotic	medication.	Given	that	our	sample	consisted	of	high-functioning	schizotypes,	
these	 results	may	 also	 indicate	potential	 neurobiological	mechanisms	of	 resilience.	 Future	
longitudinal	 studies	 testing	 this	model	 comprehensively,	 including	 serial	 structural	 imaging	
scans	 in	 the	 same	 individuals	 in	 combination	 with	 GABAergic,	 glutamatergic	 and	
dopaminergic	 neurotransmission,	 will	 be	 fundamental	 to	 understanding	 the	 mechanisms	
underlying	 the	 development	 of	 schizophrenia,	 and	 may	 provide	 a	 scientific	 basis	 for	 the	
development	 of	 novel	 interventions	 including	 facilitation	 of	 NMDA	 receptor-mediated	
neurotransmission	to	prevent	or	delay	progression	to	psychosis	in	vulnerable	individuals.	
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FIGURE	LEGENDS	
	
	
	
Figure	 1.	 (A)	Magnetic	 Resonance	 Spectroscopy	 voxel	 placement	 in	 the	 anterior	 cingulate	
cortex.	(B)	Bar	graphs	showing	metabolite	levels	(in	institutional	units)	in	each	group	(LS,	low	
schizotypy;	 HS	 =	 high	 schizotypy).	 Glu	 =	 glutamate;	 Gln	 =	 glutamine;	 Glx	 =	 glutamate	 +	
glutamine;	NAA	=	N-acetylaspartate;	Mi	=	myo-inositol;	Cr	=	creatine;	Cho	=	choline.	
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Figure	 2.	 (A)	 Decreased	 gray	 matter	 volume	 (GMV)	 in	 the	 rolandic	 operculum/superior	
temporal	gyrus	in	subjects	high	schizotypy	(HS)	compared	to	those	with	low	schizotypy	(LS).	
(B)	Increased	GMV	in	the	precuneus	and	the	anterior	cingulate	cortex	in	HS	compared	to	LS	
subjects.	 (C)	Positive	associations	between	GMV	 in	 the	precuneus	and	 levels	of	 schizotypy	
(O-LIFE	total,	upper	panel)	and	levels	of	social	functioning	(SFQ	total,	lower	panel).	Higher	O-
LIFE	 scores	 indicate	 higher	 schizotypy,	 and	 higher	 SFQ	 scores	 indicate	 poorer	 social	
functioning.	 All	 effects	 were	 considered	 significant	 at	 voxel-wise	 P	 <	 .05	 FWE	 correction;	
statistical	parametric	maps	thresholded	at	P	<	.005	uncorrected	for	display	purposes.		
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Figure	3.	(A)	Section	overlay	of	the	negative	correlation	between	glutamate	levels	and	gray	
matter	 volume	 in	 the	 anterior	 cingulate	 cortex	 (ACC)	 in	 high	 schizotypy	 subjects.	 Effects	
were	considered	significant	at	voxel-wise	P	<	.05	FWE	correction;	statistical	parametric	maps	
are	 shown	 at	 P	 <	 .005	 uncorrected	 for	 display	 purposes.	 (B)	 Plot	 depicting	 the	 negative	
correlation	between	glutamate	levels	and	grey	matter	volume	in	the	ACC.	
Psychological	Medicine	 	 Modinos	et	al.	
	 29	
TABLES	
Table	1.	Sample	Characteristics.	
	 Low	Schizotypy	
(n	=	23)	
High	Schizotypy	
(n	=	22)	
Analysis	
Age	(years)	 26.87	(5.40)	 27.36	(7.61)	 t	=	-.252	P	=	.802	
Gender	(%	female)	 47.8%	(n	=	11)	 50%	(n	=	11)	 X2	=	.021	P	=	.884	
Ethnicity	(%	white)	 73.9%	(n	=	17)	 59.1%	(n	=	13)	 X2	=	4.604	P	=	.203	
IQ	(WAIS-III	short	version)	 122.30	(13.54)	 117.41	(18.55)	 t	=	1.014	P	=	.316	
O-LIFE	Total	 16.04	(8.58)	 38.23	(12.62)	 t	=	-6.865	P	<.001	
O-LIFE	Unusual	Experiences	 .96	(1.02)	 11.59	(4.93)	 t	=	-9.926	P	<	.001	
O-LIFE	Cognitive	Disorganization	 5.48	(3.96)	 11.32	(6.69)	 t	=	-3.544	P	=	.001	
O-LIFE	Introvertive	Anhedonia	 4.78	(3.18)	 9.05	(2.50)	 t	=	-4.990	P	<	.001	
O-LIFE	Impulsive	Nonconformity	 4.83	(4.24)	 6.27	(4.60)	 t	=	-1.099	P	=	.278	
Social	Functioning	Questionnaire	Total	 4.09	(3.04)	 5.50	(2.87)	 t	=	-1.600	P	=	.117	
Daily	tobacco	use	(mean)	 .71	(3.19)	 .30	(0.75)	 t	=	.552	P	=	.584	
Daily	caffeine	use	(mean)	 1.78	(1.46)	 2.82	(2.52)	 t	=	-1.752	P	=	.087	
Alcohol	use	(median	[range])	 2	(0	–	5)	 1	(0	–	4)	 X2	=	6.047	P	=	.302	
Marijuana	use	(median	[range])	 .5	(0	–	3)	 0	(0	–	3)	 X2	=	1.767	P	=	.622	
Parental	socio-economic	status	(%	
	professional	level)	
63.6%	(n	=	14)	 70.0%	(n	=	14)	 X2	=	.573	P	=	.751	
Educational	level	(%	university	level)	 91.3%	(n	=	21)	 77.3%	(n	=	17)	 X2	=	1.685	P	=	.194	
Note:	higher	scores	on	the	Social	Functioning	Questionnaire	reflect	lower	social	functioning.	
O-LIFE	 =	 Oxford–Liverpool	 Inventory	 of	 Feelings	 and	 Experiences;	 Wechsler	 Adult	
Intelligence	Scale-III.		
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Table	2.	1H-MRS	quality	parameters	and	metabolite	levels	by	group.	
	 Low	Schizotypy	 High	Schizotypy	 	
	 Mean	 SD	 Mean	 SD	 P-value	
SNR	 25.26	 4.34	 25.73	 4.76	 .733	
Line	width	 5.04	 1.04	 4.72	 0.56	 .199	
FWHM	 0.038	 0.004	 0.036	 0.005	 .275	
Voxel	CSF	 0.24	 0.04	 0.26	 0.05	 .405	
Voxel	GM	 0.64	 0.05	 0.63	 0.05	 .429	
Voxel	WM	 0.11	 0.03	 0.11	 0.04	 .937	
Glutamate	%	CRLB	 6.17	 1.40	 5.73	 0.94	 .218	
Glutamate	 15.67	 2.51	 16.14	 2.07	 .497	
Glutamine	%	CRLB	 14.44	(n=9)	 4.07	 14.73	(n=11)	 3.50	 .869	
Glutamine	 7.04	(n=9)	 1.41	 6.70	(n=11)	 1.72	 .642	
Glx	%	CRLB	 6.87	 2.10	 6.32	 1.21	 .289	
Glx	 20.36	 3.67	 21.27	 3.48	 .398	
Creatine	%	CRLB	 2.43	 0.51	 2.50	 0.51	 .670	
Creatine	 12.15	 1.45	 12.05	 1.17	 .805	
Myo-Inositol	%	CRLB	 5.17	 2.23	 4.64	 0.90	 .299	
Myo-Inositol	 8.54	 1.60	 8.72	 1.05	 .652	
NAA	%	CRLB	 2.96	 0.56	 2.73	 0.46	 .141	
NAA	 14.88	 1.34	 15.25	 1.54	 .396	
Choline	%	CRLB	 3.13	 0.34	 3.09	 0.53	 .766	
Choline	 2.94	 0.36	 2.99	 0.46	 .699	
SNR:	 signal-to-noise	 ratio;	 CRLB:	 Cramer-Rao	 Lower	 Bounds,	 CSF:	 cerebrospinal	 fluid;	
FWHM:	 full-width-half-maximum;	 GM:	 gray	 matter;	 NAA:	 N-acetylaspartate;	 WM:	 white	
matter.	
	
	
	
